Compare NetFlix Inc (NFLX) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetFlix Inc vs Novo Nordisk A/S — how do they compare? NetFlix Inc trades at $70.49 (market cap $298.01B), while Novo Nordisk A/S trades at $38.65 (market cap $165.31B). The key difference: NetFlix Inc is the larger of the two by market cap, and Novo Nordisk A/S pays a 4.71% dividend while NetFlix Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold NetFlix Inc for 125 Days and Novo Nordisk A/S for 116 Days on average.
| NFLX | NVO | |
|---|---|---|
Market Cap | $298.01B | $165.31B |
Volume | 45,805,108 | 11,432,838 |
Sector | Media | Health |
52-Week High | $124.13 | $63.98 |
52-Week Low | $67.06 | $35.29 |
Typical Hold Time | 125 Days | 116 Days |
Enterprise Value | $303.19B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Netflix trades at $69.70, up 1.47% today, with strong fundamentals including 28.2% net margin and 49.5% ROE. The stock shows bearish technical signals despite beating earnings expectations for three consecutive quarters. Recent news highlights Netflix's live sports strategy and content investments, while analyst consensus remains bullish with a $89.78 price target representing 29% upside potential.
Netflix presents a compelling growth story with expanding profitability and strategic content investments, though technical weakness and competitive pressures warrant caution. The company's strong cash flow generation and institutional interest support long-term upside, but investors should monitor execution risks in the evolving streaming landscape.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
